Cours CannaPharmaRX, Inc. Other OTC
Actions
CPMD
US13765D1090
Produits pharmaceutiques
CA 2021 | - | CA 2022 | - | Capitalisation | 2,57 M 2,34 M |
---|---|---|---|---|---|
Résultat net 2021 | -8 M -7,3 M | Résultat net 2022 | -8 M -7,3 M | VE / CA 2021 | - |
Dette nette 2021 | 8,99 M 8,2 M | Dette nette 2022 | 14,52 M 13,25 M | VE / CA 2022 | - |
PER 2021 |
-0,11
x | PER 2022 |
-0,25
x | Employés | - |
Rendement 2021 * |
-
| Rendement 2022 |
-
| Flottant | 97,33% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Dean Medwid
CEO | Chief Executive Officer | - | 01/06/23 |
Dominick Colvin
CEO | Chief Executive Officer | 55 | 01/01/17 |
Oliver Foeste
DFI | Director of Finance/CFO | 48 | 13/10/23 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Rick Orman
CHM | Chairman | 74 | 23/04/19 |
Dominick Colvin
CEO | Chief Executive Officer | 55 | 01/01/17 |
Anthony Panek
BRD | Director/Board Member | 39 | 25/08/23 |
Varia. 1 janv. | Capi. | |
---|---|---|
+25,83% | 661 Md | |
+26,84% | 566 Md | |
-6,76% | 352 Md | |
+20,34% | 332 Md | |
+3,00% | 283 Md | |
+14,53% | 231 Md | |
+5,33% | 200 Md | |
-8,96% | 195 Md | |
-6,26% | 145 Md |